TRIDENT LIFELINE Financial Statement Analysis
|
||
The Revenues of TRIDENT LIFELINE have increased by 40.82% YoY .
The Earnings Per Share (EPS) of TRIDENT LIFELINE has increased by 5.54 % YoY. |
REVENUES |
OPERATING MARGIN |
PROFIT AFTER TAX |
EPS |
ROCE |
TRIDENT LIFELINE Last 5 Annual Financial Results
[BOM: 543616]
Consolidated | Mar2024 | Mar2023 | Mar2022 |
---|---|---|---|
Revenues | ₹45 Cr | ₹32 Cr | ₹22 Cr |
Expenses | ₹36 Cr | ₹25 Cr | ₹19 Cr |
Operating Profit (Excl OI) | ₹8.23 Cr | ₹6.27 Cr | ₹2.71 Cr |
Other Income | ₹2.08 Cr | ₹1.16 Cr | ₹0.60 Cr |
Interest | ₹0.65 Cr | ₹0.48 Cr | ₹0.13 Cr |
Depreciation | ₹0.97 Cr | ₹0.37 Cr | ₹0.20 Cr |
Profit Before Tax | ₹8.70 Cr | ₹6.58 Cr | ₹2.98 Cr |
Profit After Tax | ₹5.94 Cr | ₹6.02 Cr | ₹3.95 Cr |
Consolidated Net Profit | ₹6.34 Cr | ₹6.02 Cr | ₹3.95 Cr |
Earnings Per Share (Rs) | ₹5.52 | ₹5.23 | ₹4.93 |
PAT Margin (%) | 13.31 | 18.99 | 18.14 |
ROE(%) | 12.52 | 24.21 | 83.23 |
ROCE(%) | 15.32 | 23.60 | 43.21 |
Total Debt/Equity(x) | 0.37 | 0.17 | 0.52 |
Key Financials |
||
Market Cap | : | ₹ 316.3 Cr |
Revenue (TTM) | : | ₹ 41.9 Cr |
Net Profit(TTM) | : | ₹ 6.4 Cr |
EPS (TTM) | : | ₹ 5.6 |
P/E (TTM) | : | 49.2 |
Industry Peers & Returns | 1W | 1M | 1Y |
TRIDENT LIFELINE | -3.5% | -11.5% | 37.4% |
SUN PHARMACEUTICAL INDUSTRIES | -0.1% | 1.7% | 45.7% |
CIPLA | 1.7% | 0.5% | 23.7% |
DR REDDYS LABORATORIES | 5.7% | 12.4% | 18.5% |
ZYDUS LIFESCIENCES | -1.4% | 3.1% | 44.8% |
DIVIS LABORATORIES | -0.1% | -2.2% | 56.9% |
MANKIND PHARMA | 4.2% | 9.8% | 49.8% |
TORRENT PHARMACEUTICALS | 2.2% | 10.6% | 61.7% |
LUPIN | 4.1% | 5.1% | 71.7% |
TRIDENT LIFELINE Revenues
[BOM: 543616]
Y-o-Y | 40.82 % |
5 Yr CAGR | 43.19 % |
Years | Revenues | % Change | |
---|---|---|---|
Mar2024 | ₹45 Cr | 40.82 | |
Mar2023 | ₹32 Cr | 45.59 | |
Mar2022 | ₹22 Cr | - |
TRIDENT LIFELINE Operating Profit
[BOM: 543616]
Y-o-Y | 31.41 % |
5 Yr CAGR | 74.34 % |
Years | Operating Profit | % Change | |
---|---|---|---|
Mar2024 | ₹8.23 Cr | 31.41 | |
Mar2023 | ₹6.27 Cr | 131.30 | |
Mar2022 | ₹2.71 Cr | - |
Operating Margins | |
---|---|
Y-o-Y | -6.68 % |
5 Yr CAGR | 21.78 % |
Years | Operating Margin% | % Change | |
---|---|---|---|
Mar2024 | 18.45% | -6.68 | |
Mar2023 | 19.77% | 58.92 | |
Mar2022 | 12.44% | - |
TRIDENT LIFELINE Profit After Tax
[BOM: 543616]
Y-o-Y | 5.47 % |
5 Yr CAGR | 26.76 % |
Years | Profit After Tax | % Change | |
---|---|---|---|
Mar2024 | ₹6.34 Cr | 5.47 | |
Mar2023 | ₹6.02 Cr | 52.36 | |
Mar2022 | ₹3.95 Cr | - |
PAT Margins | |
---|---|
Y-o-Y | -29.91 % |
5 Yr CAGR | -14.34 % |
Years | PAT Margin(%) | % Change | |
---|---|---|---|
Mar2024 | 13.31 % | -29.91 | |
Mar2023 | 18.99 % | 4.69 | |
Mar2022 | 18.14 % | - |
TRIDENT LIFELINE Earnings Per Share (EPS)
[BOM: 543616]
Y-o-Y | 5.54 % |
5 Yr CAGR | 5.81 % |
Years | EPS | % Change | |
---|---|---|---|
Mar2024 | ₹5.52 | 5.54 | |
Mar2023 | ₹5.23 | 6.09 | |
Mar2022 | ₹4.93 | - |
TRIDENT LIFELINE Return on Capital Employed (ROCE)
[BOM: 543616]
Y-o-Y | -35.08 % |
5 Yr CAGR | -40.46 % |
Years | ROCE | % Change | |
---|---|---|---|
Mar2024 | 15.32% | -35.08 | |
Mar2023 | 23.6% | -45.38 | |
Mar2022 | 43.21% | - |
TRIDENT LIFELINE Share Price vs Sensex
Current Share Price | : | ₹275.0 |
Current MarketCap | : | ₹ 316.3 Cr |
Updated EOD on | : | Dec 19,2024 |
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
TRIDENT LIFELINE | -3.5% |
-11.5% |
37.4% |
SENSEX | -5% |
0.6% |
9.2% |
TRIDENT LIFELINE related INDICES
You may also like the below Video Courses
FAQ about TRIDENT LIFELINE Financials
How the annual revenues of TRIDENT LIFELINE have changed ?
The Revenues of TRIDENT LIFELINE have increased by 40.82% YoY .
How the Earnings per Share (EPS) of TRIDENT LIFELINE have changed?
The Earnings Per Share (EPS) of TRIDENT LIFELINE has increased by 5.54 % YoY .
SUN PHARMACEUTICAL INDUSTRIES LTD vs CIPLA LTD vs DR REDDYS LABORATORIES LTD
ZYDUS LIFESCIENCES LTD vs DIVIS LABORATORIES LTD vs